Literature DB >> 921253

Discrepant results of amphotericin B assays on fresh versus frozen serum samples.

R M Bannatyne, R Cheung.   

Abstract

Amphotericin B assays on frozen serum samples (-20 degrees C) generally underestimate the serum levels obtained on promptly processed samples. The degree of the discrepancy is variable and independent of the length of time stored.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 921253      PMCID： PMC429966          DOI： 10.1128/AAC.12.4.550

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

1.  Stability of amphotericin B in fungal culture media.

Authors:  S C Cheung; G Medoff; D Schlessinger; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1975-10       Impact factor: 5.191

2.  Stability of amphotericin B in infusion bottles.

Authors:  E R Block; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1973-12       Impact factor: 5.191

3.  Microassay foramphotericin B.

Authors:  R M Bannatyne; R Cheung; H R Devlin
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

4.  The effect of pH and of temperature on the stability and bioactivity of nystatin and amphotericin B.

Authors:  J M Hamilton-Miller
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765
  4 in total
  6 in total

1.  Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.

Authors:  A Louie; P Kaw; P Banerjee; W Liu; G Chen; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.

Authors:  A Louie; W Liu; D A Miller; A C Sucke; Q F Liu; G L Drusano; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

3.  Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.

Authors:  A Louie; P Banerjee; G L Drusano; M Shayegani; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

5.  Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.

Authors:  R E Lewis; B C Lund; M E Klepser; E J Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

6.  Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard.

Authors:  G G Granich; G S Kobayashi; D J Krogstad
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.